AstraZeneca PLC (AZN)vsCareCloud, Inc. (CCLD)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
CCLD
CareCloud, Inc.
$2.05
+0.49%
HEALTHCARE · Cap: $87.11M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 47604% more annual revenue ($61.37B vs $128.64M). AZN leads profitability with a 17.0% profit margin vs 6.2%. CCLD appears more attractively valued with a PEG of 0.31. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
CCLD
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
+65.8%
Fair Value
$6.55
Current Price
$2.05
$4.50 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Growing faster than its price suggests
16.4% revenue growth
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Moderate valuation
Smaller company, higher risk/reward
6.2% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : CCLD
The strongest argument for CCLD centers on PEG Ratio, Revenue Growth. Revenue growth of 16.4% demonstrates continued momentum. PEG of 0.31 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : CCLD
The primary concerns for CCLD are P/E Ratio, Market Cap, Profit Margin. Debt-to-equity of 3.10 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while CCLD is a growth play — different risk/reward profiles.
CCLD carries more volatility with a beta of 1.50 — expect wider price swings.
CCLD is growing revenue faster at 16.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 51/100), backed by strong 17.0% margins. CCLD offers better value entry with a 65.8% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
CareCloud, Inc.
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
CareCloud, Inc., a healthcare information technology (IT) company, provides a suite of cloud-based solutions and related business services to healthcare providers and hospitals primarily in the United States. The company is headquartered in Somerset, New Jersey.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?